PUBLICAÇÕES científicas

/cun/pt/investigacion/publicaciones-cientificas/areaMain/02
  • Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

    Lorusso D (#1), Hilpert F (#2,3), González Martin A (4,5), Rau J (6), Ottevanger P (7), Greimel E (8), Lück HJ (9), Selle F (10), Colombo N (11), Kroep JR (12), Mirza MR (13), Berger R (14), Pardo B (15), Grischke EM (16), Berton-Rigaud D (17), Martinez-Garcia J (18), Vergote I (19), Redondo A (20), Cardona A (21), Bastière-Truchot L (21), du Bois A (22), Kurzeder C (22,23); PENELOPE trial investigators.

    (1) Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy
    (2) Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany (affiliation when work was performed).
    (3) Mammazentrum am Krankenhaus Jerusalem, Hamburg, Germany.
    (4) Grupo Español de Investigación en Cáncer de Ovario (GEICO) and MD Anderson Cancer Center Spain, Madrid, Spain (affiliation when work was performed).
    (5) Clínica Universidad de Navarra, Madrid, Spain.
    (6) Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Germany.
    (7) Dutch Gynaecological Oncology Group (DGOG) and Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
    (8) Medical University Graz, Graz, Austria.
    (9) AGO and Gynäkologisch-Onkologische Praxis am Pelikanplatz, Hannover, Germany.
    (10) Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Groupe Hospitalier Diaconesses Croix Saint-Simon and Alliance Pour la Recherche en Cancérologie, Paris, France.
    (11) Mario Negri Gynecologic Oncology (MaNGO) group, IEO, European Institute of Oncology IRCCS, and University of Milan-Bicocca, Milan, Italy.
    (12) DGOG and Department of Medical Oncology, Leids Universitair Medisch Centrum, Leiden, Netherlands.
    (13) Nordic Society of Gynaecological Oncology (NSGO) and Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
    (14) AGO-Austria and University Hospital for Gynaecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria.
    (15) GEICO and Medical Oncology Department, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain.
    (16) AGO and University Hospital of Gynecology and Obstetrics, Tübingen, Germany.
    (17) GINECO and Integrated Center for Oncology Nantes-Angers, Nantes, France.
    (18) GEICO and Medical Oncology Service, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Spain.
    (19) AGO and Leuven Cancer Institute, University Hospital Leuven, Leuven, Belgium.
    (20) GEICO and Medical Oncology Department, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
    (21) F. Hoffmann-La Roche, Basel, Switzerland.
    (22) AGO and Kliniken Essen Mitte, Essen, Germany.
    (23) Department of Gynecology and Gynecological Oncology, University Hospital Basel, University of Basel, Basel, Switzerland.
    #Contributed equally

    International Journal of Gynecological Cancer 15 de AGOSTO de 2019

  • Preoperative Circulating Succinate Levels as a Biomarker for Diabetes Remission After Bariatric Surgery

    Ceperuelo-Mallafré V (1,2), Llauradó G (2,3), Keiran N (1,2), Benaiges E (1,2), Astiarraga B (1,2,4), Martínez L (1), Pellitero S (2,5), González-Clemente JM (2,6), Rodríguez A (7), Fernández-Real JM (4), Lecube A (8), Megía A (1,2), Vilarrasa N (2,9), Vendrell J (10,2,11), Fernández-Veledo S (12,2).

    (1) Institut d'Investigació Sanitària Pere Virgili, Endocrinology and Nutrition Service, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
    (2) CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
    (3) Department of Endocrinology and Nutrition, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.
    (4) Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona, CIBEROBN (CB06/03/010) and ISCIII, Girona, Spain.
    (5) Department of Endocrinology and Nutrition, Germans Trias i Pujol Research Institute, Barcelona, Spain.
    (6) Department of Endocrinology and Nutrition, Hospital de Sabadell, Corporació Sanitària Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (Universitat Autònoma de Barcelona), Sabadell, Spain.
    (7) Metabolic Research Laboratory, Clínica Universidad de Navarra, CIBEROBN, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
    (8) Endocrinology and Nutrition Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
    (9) Obesity Unit and Endocrinology and Nutrition Departments, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
    (10) Institut d'Investigació Sanitària Pere Virgili, Endocrinology and Nutrition Service, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
    (11) Rovira I Virgili University, Tarragona, Spain.
    (12) Institut d'Investigació Sanitària Pere Virgili, Endocrinology and Nutrition Service, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain

    Diabetes Care 02 de AGOSTO de 2019

  • Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma

    Mateos MV (1), Blacklock H (2), Schjesvold F (3), Oriol A (4), Simpson D (5), George A (6), Goldschmidt H (7), Larocca A (8), Chanan-Khan A (9), Sherbenou D (10), Avivi I (11), Benyamini N (12), Iida S (13), Matsumoto M (14), Suzuki K (15), Ribrag V (16), Usmani SZ (17), Jagannath S (18), Ocio EM (19), Rodriguez-Otero P (20), San Miguel J (20), Kher U (21), Farooqui M (21), Liao J (21), Marinello P (21), Lonial S (22); KEYNOTE-183 Investigators.

    (1) Complejo Asistencial Universitario de Salamanca/IBSAL, Salamanca, Spain.
    (2) Middlemore Hospital, Auckland, New Zealand.
    (3) Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo, Norway.
    (4) Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Triasi Pujol, Barcelona, Spain.
    (5) North Shore Hospital, Auckland, New Zealand.
    (6) Wellington Blood and Cancer Center, Wellington, New Zealand.
    (7) University Hospital Heidelberg and National Center of Tumor Diseases in Heidelberg, Heidelberg, Germany.
    (8) Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
    (9) Mayo Clinic, Jacksonville, FL, USA.
    (10) University of Colorado Cancer Center, Denver, CO, USA.
    (11) Sourasky Medical Center, Haifa, Israel.
    (12) Rambam Health Care Campus, HaAliya HaShniya, Israel.
    (13) Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Japan.
    (14) National Hospital Organization, Shibukawa Medical Center, Shibukawa, Gunma, Japan.
    (15) Japanese Red Cross, Tokyo, Japan.
    (16) Institut Gustave Roussy, Villejuif, France.
    (17) Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
    (18) The Mount Sinai Medical Hospital, New York, NY, USA.
    (19) Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
    (20) Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
    (21) Merck & Co, Kenilworth, NJ, USA.
    (22) Winship Cancer Institute, Emory University, Atlanta, GA, USA.

    The Lancet. Haematology 18 de JULHO de 2019

  • Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma

    Usmani SZ (1), Schjesvold F (2), Oriol A (3), Karlin L (4), Cavo M (5), Rifkin RM (6), Yimer HA (7), LeBlanc R (8), Takezako N (9), McCroskey RD (10), Lim ABM (11), Suzuki K (12), Kosugi H (13), Grigoriadis G (14), Avivi I (15), Facon T (16), Jagannath S (17), Lonial S (18), Ghori RU (19), Farooqui MZH (19), Marinello P (19), San-Miguel J (20); KEYNOTE-185 Investigators.

    (1) Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
    (2) Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo, Norway.
    (3) Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain.
    (4) Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
    (5) Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
    (6) Rocky Mountain Cancer Centers, Denver, CO, USA.
    (7) Texas Oncology, Tyler, TX, USA.
    (8) Centre Intégré Universitaire de Santé et de Services Sociaux de l'Est de L'Ile de Montréal, University of Montreal, Montreal, QC, Canada.
    (9) Disaster Medical Center, Tokyo, Japan.
    (10) Northwest Medical Specialties, PLLC, Puyallup, WA, USA.
    (11) Austin Health, Austin Hospital, Heidelberg, VIC, Australia.
    (12) Japanese Red Cross Medical Center, Tokyo, Japan.
    (13) Ogaki Municipal Hospital, Ogaki, Japan.
    (14) Monash Health, Melbourne, VIC, Australia.
    (15) Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
    (16) Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France.
    (17) Mount Sinai Hospital, New York, NY, USA.
    (18) Winship Cancer Institute, Emory University, Atlanta, GA, USA.
    (19) Merck & Co, Inc, Kenilworth, NJ, USA.
    (20) Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.

    The Lancet. Haematology 18 de JULHO de 2019

  • Prevalence and risk factors for hypoparathyroidism following total thyroidectomy in Spain

    Díez JJ (1,2), Anda E (3), Sastre J (4), Pérez Corral B (5), Álvarez-Escolá C 6, Manjón L (7), Paja M (8), Sambo M (9), Santiago Fernández P (10), Blanco Carrera C (11), Carlos Galofré J (12), Navarro E (13), Zafón C (14), Sanz E 14, Oleaga A (8), Bandrés O (15), Donnay S (16), Megía A (17), Picallo M (9), Sánchez Ragnarsson C (7), Baena-Nieto G (18), García JCF (19), Lecumberri B (6), de la Vega MS (20), Romero-Lluch AR (13), Iglesias P (21,22).

    (1) Department of Endocrinology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
    (2) Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
    (3) Department of Endocrinology, Complejo Hospitalario de Navarra, Pamplona, Spain.
    (4) Department of Endocrinology, Complejo Hospitalario de Toledo, Toledo, Spain.
    (5) Department of Endocrinology, Complejo Asistencial Universitario de León, León, Spain.
    (6) Department of Endocrinology, Hospital Universitario La Paz, Madrid, Spain.
    (7) Department of Endocrinology, Hospital Universitario Central de Asturias, Oviedo, Spain.
    (8) Department of Endocrinology, Hospital Universitario de Basurto, Bilbao, Spain.
    (9) Department of Endocrinology, Hospital Universitario Gregorio Marañón, Madrid, Spain.
    (10) Department of Endocrinology, Complejo Hospitalario de Jaén, Jaén, Spain.
    (11) Department of Endocrinology, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.
    (12) Department of Endocrinology, Clínica Universidad de Navarra, Pamplona, Spain.
    (13) Department of Endocrinology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
    (14) Department of Endocrinology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
    (15) Department of Endocrinology, Hospital Royo Villanova, Zaragoza, Spain.
    (16) Department of Endocrinology, Fundación Hospital de Alcorcón, Alcorcón, Madrid, Spain.
    (17) Department of Endocrinology, Hospital Universitario de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, Ciberdem, Tarragona, Spain.
    (18) Department of Endocrinology, Hospital de Jerez, Jerez de la Frontera, Cádiz, Spain.
    (19) Department of Endocrinology, Hospital Virgen de la Victoria, Málaga, Spain.
    (20) Department of Endocrinology, Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain.
    (21) Department of Endocrinology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
    (22) Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.

    Endocrine 17 de JULHO de 2019

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra